. 2023 Jul 12;12(8):e230122. doi: 10.1530/EC-23-0122
This work is licensed under a Table 1.
Baseline characteristics of included patients.
| Addison’s disease (n = 82) | Congenital adrenal hyperplasia (n = 80) | P-value | |
|---|---|---|---|
| Women, n (%) | 51 (62.2) | 50 (64.4) | >0.999 |
| Age (years), median (IQR)a | 55 (39–67) | 39 (29–47) | <0.001 |
| Ethnicity, n (%) | |||
| White | 73 (89.0) | 62 (77.5) | 0.059 |
| Asian or Asian British | 6 (7.3) | 14 (17.5) | 0.058 |
| Black, African, Caribbean, or Black British | 2 (2.4) | 4 (5.0) | 0.440 |
| Other ethnic group | 1 (1.2) | – | >0.999 |
| BMI (kg/m2), median (IQR) | 25.7 (23.2–30.0) | 27.9 (22.3-31.8) | 0.449 |
| Years since diagnosis, median (IQR) | 16 (8–28) | – | – |
| Comorbidities | |||
| Autoimmune diseases, n (%)a | 35 (42.7) | 8 (10.0) | <0.001 |
| Hypothyroidism, n | 26 | 1 | |
| Type 1 diabetes mellitus, n | 12 | 1 | |
| Premature ovarian failure, n | 9 | – | |
| Pernicious anaemia, n | 4 | 1 | |
| Hyperthyroidism, n | 4 | 1 | |
| Hypoparathyroidism, n | 3 | – | |
| Vitiligo, n | 3 | – | |
| Coeliac disease, n | 2 | 1 | |
| Alopecia, n | 2 | / | |
| Ulcerative colitis, n | 1 | 1 | |
| Multiple sclerosis, n | – | 1 | |
| Systemic lupus erythematosus, n | 1 | 1 | |
| Sarcoidosis, n | 1 | – | |
| Pyoderma gangrenosum, n | 1 | – | |
| Hypertension, n (%) | 11 (13.4) | 4 (5.0) | 0.102 |
| Asthma/COPD, n (%)a | 11 (13.4) | 3 (3.8) | 0.047 |
| Bone loss (osteopaenia/osteoporosis), n (%) | 10 (12.2) | 6 (7.5) | 0.431 |
| Reduced fertility,b n (%) | 9 (11.0) | 7 (8.8) | 0.793 |
| Cardiovascular events, n (%)a | 8 (9.8) | 1 (1.3) | 0.034 |
| Type-2 diabetes mellitus, n (%) | 5 (6.1) | 4 (5.0) | >0.999 |
| Sleep apnoea, n (%) | 3 (3.7) | – | 0.246 |
| Depression, n (%) | 3 (3.7) | 6 (7.5) | 0.325 |
| History of cancer, n (%) | 2 (2.4) | 1 (1.3) | >0.999 |
| Candidiasis, n (%) | 1 (1.2) | – | >0.999 |
| Testicular adrenal rest tumours, n (% of men) | – | 7 (23.3) | |
| Recurrent lower respiratory tract infections, n (%) | – | 2 (2.5) | 0.242 |
| Ehlers-Danlos syndrome, n (%) | – | 2 (2.5) | 0.242 |
| Charlson Comorbidity Index, n (%) | |||
| 0a | 28 (34.1) | 57 (71.3) | <0.001 |
| 1 | 15 (18.3) | 15 (18.8) | >0.999 |
| ≥2a | 39 (47.6) | 8 (10.0) | <0.001 |
| Glucocorticoid replacement therapy | |||
| Immediate-release hydrocortisone, n (%)a | 80 (97.6) | 36 (45.0) | <0.001 |
| Prednisolone, n (%)a | 1 (1.2) | 23 (28.8) | <0.001 |
| Chronocort, n (%) | – | 11 (13.8) | <0.001 |
| Dexamethasone, n (%)a | – | 6 (7.5) | 0.013 |
| Plenadren, n (%) | 1 (1.2) | – | >0.999 |
| Hydrocortisone + prednisolone, n (%) | – | 1 (1.3) | 0.494 |
| Prednisolone + dexamethasone, n (%) | – | 1 (1.3) | 0.494 |
| None, n (%) | – | 2 (2.5) | 0.242 |
| Hydrocortisone-equivalent dose, median (IQR)c | 20 (20–25) | 24 (20–30) | 0.328 |
| Mineralocorticoid replacement, n (%)a | 79 (96.3) | 50 (68.5) | <0.001 |
| Fludrocortisone dose, median (IQR)a | 100 (100–188) | 200 (119–200) | <0.001 |
| DHEA replacement, n (% of women) | 9 (17.6) | – |
aSignificant figures; bincludes patients with premature ovarian failure; cconversion factors: prednisolone 0.25; dexamethasone 0.025.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DHEA, dehydroepiandrosterone; IQR, interquartile range.